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Intramyocardial Transplantation of Mesenchymal Stromal Cells for Chronic Myocardial 
Ischemia and Impaired Left Ventricular Function: Results of the MESAMI 1 Pilot Trial.  
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STRUCTURED ABSTRACT 
 
Background: The MESAMI 1 trial was a bicentric pilot study designed to test the feasibility and 
safety of intramyocardially injected autologous bone marrow-derived mesenchymal stromal cells 
(MSCs) for the treatment of ischemic cardiomyopathy. 
Methods and Results: The study included 10 patients with chronic myocardial ischemia, left 
ventricular (LV) ejection fractions (EFs) of ≤35%, and reversible perfusion defects who were on stable 
optimal medical therapy and were not candidates for revascularization. MSCs (mean: 61.5×10
6 
cells 
per patient) were injected into 10-16 viable sites at the border of the LV scar via a NOGA-guided 
catheter. Both primary endpoints, feasibility (successful harvest, expansion, and injection of 
autologous MSCs) and safety (absence of severe adverse events [SAEs]) were met in all 10 patients at 
the 1-month follow-up time point, and none of the SAEs reported during the full 2-year follow-up 
period were attributable to the study intervention. The results of secondary efficacy endpoint analyses 
identified significant improvements from baseline to Month 12 in LVEF (29.4±2.0% versus 
35.7±2.5%; p=0.003), LV end-systolic volume (167.8±18.8 mL versus 156.1±28.6 mL; p=0.04), 6-
minute walk test and NYHA functional class. 
Conclusions:  Our results suggest that autologous MSCs can be safely administered to the hearts of 
patients with severe, chronic, reversible myocardial ischemia and impaired cardiac function and may 
be associated with improvements in cardiac performance, LV remodeling, and patient functional 
status. A randomized, double blind, multicenter, placebo-controlled clinical trial (MESAMI 2) will 
evaluate the efficacy of this treatment approach in a larger patient population.  
Clinical Trial Registration: Unique identifier: NCT01076920 
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INTRODUCTION 
 
Ischemic cardiomyopathies continue to be among the leading causes of death in western countries, and 
although many important advances in the treatment of heart failure have evolved during the last 
decade, most focus only on relieving symptoms and preventing disease progression. Strategies for 
revascularizing the myocardium and limiting ventricular remodeling must be considered before more 
invasive interventions are performed, and researchers are currently developing a variety of therapies 
with stem cells that have been obtained from numerous sources and can provide trophic and paracrine 
support, or even replace the dying cells. Adult bone marrow-derived mesenchymal stromal cells 
(MSCs) are a particularly promising cell type, because of their capacity to differentiate into endothelial 
cells, to participate in the development of new blood vessels in ischemic tissues, and to promote the 
activity of resident cardiac cells. Preliminary evidence of the efficacy of MSC injection for treatment 
of acute and chronic myocardial infarction has been observed in both animal models and early clinical 
trials (1-4), but improvements in symptoms, functional status, or ejection fraction (EF) have not been 
achieved in recent placebo-controlled clinical trials with bone marrow-derived or adipose tissue-
derived MSCs (5,6). 
 
The inconsistent results achieved in trials of MSC therapy could be caused by a variety of factors, 
including variations in the methods used for cell selection, culture, and delivery. Thus, the primary 
objective of the MESAMI program is to develop a fully standardized regimen for autologous MSC 
selection, culture, and administration that can serve as a foundation for the industrialization of cell 
therapy during the next decade. Here, we report the results of the phase-I MESAMI 1 trial, which was 
designed to provide an initial assessment of the safety and feasibility of autologous MSC therapy in 
patients with severe chronic myocardial ischemia and impaired cardiac function. 
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METHODS 
 
Study design and patient population 
The bicentric MESAMI trial was a pilot, phase 1, prospective, non-randomized, open-label 
investigation of the feasibility and safety of autologous MSC administration for the treatment of 
patients with severe left ventricular dysfunction secondary to coronary artery disease (CAD). The 
study protocol was approved by the ethics review board of Toulouse 1 CPP (Comité de Protection des 
Personnes), and the study was conducted in accordance with the Declaration of Helsinki and under an 
Investigational National Drug Application from the French National Medicines Agency (ANSM: 
Agence Nationale de Sécurité du Médicament, France). All patients provided written informed 
consent, and the study is registered at clinicalTrials.gov (registration no. NCT01076920). 
The study was composed of 4 stages: 1) assessment of a patient’s eligibility for inclusion, 2) bone 
marrow aspiration and MSC isolation/expansion, 3) MSC injection, and 4) the follow-up period, 
which consisted of five visits. Day 0 was defined as the day of intramyocardial cell delivery. After 
MSC injection, patients remained in the hospital and were observed for at least 48 hours before 
discharge (Figure 1). 
 
Patients between 18 and 75 years of age with chronic coronary artery disease (CAD), left ventricular 
(LV) ejection fractions (EF) of 35% or less, and either Class II-IV heart failure as defined by the New 
York Heart Association (NYHA) or Class III-IV angina pectoris as assessed by the Canadian 
Cardiovascular Society, were eligible for inclusion. Patients also must have had reversible perfusion 
defects in 2 or more of 17 AHA-defined LV segments (as assessed by single-photon emission 
computed tomography [SPECT]), no possibility for additional coronary artery bypass surgery or 
percutaneous coronary intervention (PCI), and an implanted, functional, automated cardiovertor 
defibrillator (ICD). All patients were required to be on optimal pharmacological therapy, and their 
medical therapy must have been stable for at least one month before the date of eligibility assessment. 
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Patients were excluded if they had undergone revascularization (PCI or coronary artery bypass 
grafting [CABG]) or cardiac resynchronization therapy during the previous 3 months, or if an 
additional revascularization procedure was planned for within the next 30 days. Patients were also 
excluded if they had acute coronary syndrome, sustained ventricular arrhythmias, chronic atrial 
fibrillation, wall thickness in the target region of less than 8 mm (as determined by two-dimensional 
echocardiography), LV thrombus, severe peripheral vascular disease that would preclude femoral 
artery access (determined at the time of the first catheterization procedure), aortic stenosis with valve 
area of less than 1 cm
2
 (which would prohibit catheter access to the LV), positive serological test 
results for human immunodeficiency virus or hepatitis, active uncontrolled infection, a prosthetic 
aortic valve, current neoplasm, or a history of neoplasm within the last 3 years. 
 
Study endpoints 
The primary endpoints of this investigation were feasibility and safety at the one-month follow-up 
time point.  Feasibility was deﬁned as successful completion of the bone marrow aspiration, cell 
culture, and percutaneous intramyocardial injection procedures. The safety endpoint was defined as 
the incidence of treatment-related serious adverse events (SAEs) that occurred during the treatment 
procedure or during follow-up. SAEs were defined as events leading to hospitalization, death, or 
persistent or significant disability, including systemic embolism (stroke), major bleeding, and major 
adverse cardiac events (MACEs) (e.g., non-fatal MI, worsening heart failure, sustained ventricular 
arrhythmias). SAEs, non-serious adverse events, observations made during physical examinations, and 
regular vital sign measurements were recorded at each follow-up visit for a total of two years. The 
occurrence of post-injection arrhythmia was also evaluated at each visit via 12-lead electrocardiogram 
(ECG) and ICD monitoring. 
 
Secondary endpoints were assessed at baseline (M0) and after 3 months (M3) and 12 months (M12) of 
follow-up. Secondary endpoints included changes from baseline in LVEF (as assessed by 
echocardiography), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), two-
dimensional speckle-tracking echocardiography (2D-STE) longitudinal strain analyses, exercise peak 
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oxygen consumption per unit time (peak VO2), the 6-minute walk test, NYHA functional 
classification, and quality of life (Minnesota Living With Heart Failure Questionnaire [MLHFQ]). The 
6-minute walk test was performed as recommended by the American Thoracic Society. Perfusion was 
determined by SPECT imaging and included the summed rest and summed stress perfusion scores 
(SRS and SSS, respectively), as well as the summed difference score (SDS), which was calculated as 
the difference between stress and rest perfusion in each LV segment. 
 
MSC isolation and expansion 
Bone marrow aspiration was performed from the iliac crest with local anesthesia; 15-20 mL of aspirate 
was collected and immediately transported at room temperature to GMP facilities located at the French 
Blood Establishment (Etablissement Français du Sang, Midi-Pyrénées and Centre-Atlantique, France). 
Cell culture was performed according to a protocol that has been approved by both the Graft Group of 
French Bone Marrow Transplant and Cellular Therapy Society and the ANSM (7). Cell preparations 
were screened for human immunodeficiency virus types 1 and 2, syphilis, human T-lymphotropic 
virus type 1 and 2, and hepatitis B and C. Preparations that were positive for syphilis remained eligible 
for the trial, but preparations that were positive for any of the other screening tests were excluded. 
 
Total duration of the cell-culture protocol was 17±1 days, and the initial cell density was 5×10
4
 
cells/cm². Cells were cultured at 37°C and 5% CO2 in flasks (Cellstack, MACOPHARMA) with 
medium containing α-minimal essential medium (α-MEM) or Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum, 1 ng/mL fibroblast growth factor 2 (both GMP grade) and 
antibiotics. Non-adherent cells were removed after 48 to 72 hours (during the first change of medium) 
and the medium was subsequently changed twice per week; bacteriological analysis (aerobic and 
anaerobic blood culture) was performed on the supernatant collected during the last medium change. 
After 17 days of culture, the cells were washed with phosphate buffered saline (PBS), detached with 
trypsin, and counted, and their phenotype was analysed via flow cytometry for the expression of 
CD45, CD14, CD73, CD90, and CD13; then, the cells were washed three times in PBS without Ca
++
 
and Mg
++
 and resuspended in a solution of human albumin (4%) at a concentration of 20×10
6
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cells/mL. Cell viability was assessed via the trypan-blue exclusion method. Bacteriological analyses 
were performed, and the expression of human telomerase reverse transcriptase was evaluated, but the 
result was not a liberator test. Preparations that contained more than 30×10
6
 to 60×10
6
 cells, with 
>75% viability, <6% CD45 and CD14 expression, and >80% CD90, CD13, and CD73 expression 
were approved for administration to study patients. 
 
Cell delivery 
MSCs were transendocardially administered via the NOGA XP system and an 8-F Myostar mapping-
injection catheter (Biologics Delivery Systems Group, Johnson & Johnson, Irwindale, CA). Each 
patient received 10 to 16 (200-µL) injections (total volume 2000-3200 µL) in regions of viable, 
dysfunctional myocardium, which were identified via electromechanical mapping and defined by a 
univoltage potential of 4 mV or greater and reduced longitudinal linear shortening. Trans-thoracic 
echocardiograms were obtained for each patient immediately after cell injection and again before 
patient discharge and examined for evidence of pericardial effusion. 
 
Cardiac imaging 
Measurements were performed blinded at two independent core-imaging laboratories: the SPECT core 
Lab (A. Manrique, N. Piriou, D. Guijarro), and the echo core lab (Th. Le Tourneau). 
 
SPECT imaging 
Stress SPECT imaging was performed (8) under effort- and/or adenosine-induced stress (0.14 mg/kg 
per min for 6 minutes) at baseline, 3 months, and 12 months after cell injection. Thallium-201 was 
injected 3-5 minutes after adenosine infusion or immediately after effort-induced stress. Resting 
images were obtained after a second injection of Thallium-201 30 minutes later. Reconstructed images 
yielded long and short-axis projections oriented perpendicular to the heart’s axis; short-axis slices 
were displayed in polar map format and adjusted for peak myocardial activity (100%). The 
myocardium was divided into 17 segments as recommended by the AHA/American College of 
Cardiology (9).  Myocardial perfusion was analyzed with Quantitative Gated SPECT software 
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(Cedars-Sinai Medical Center, Los Angeles, California), and segment tracer activity was categorized 
on a 5-point scale according to the following criteria: 0, normal perfusion with tracer activity between 
80% and 100%; 1, tracer activity between 70% and 79%; 2, tracer activity between 50% and 69%; 3, 
tracer activity between 20% and 49%; and 4, tracer activity of less than 19%. Perfusion defects were 
considered present whenever tracer activity was less than 79% of maximum. Segmental scores while 
the patient was under stress were summed to calculate the patient’s summed stress score (SSS), 
segmental scores while the patient was at rest were summed to calculate the summed rest score (SRS), 
and the summed difference score (SDS) was calculated as the difference between the SSS and the 
SRS. 
 
Thallium-201 SPECT imaging was performed at baseline, 3 months, and 12 months after cell injection 
via a rest-redistribution protocol and by using a standard camera to assess myocardial viability. The 
LV was divided into 17 segments as defined by the AHA for all analyses (8), and the activity of each 
LV segment was expressed as the mean activity of all pixels in the segment divided by the highest 
pixel activity observed in the myocardium. Each segment was defined as viable (uptake ≥50%) or non-
viable (uptake <50%).  
 
Transthoracic echocardiography 
Transthoracic echocardiography was performed via a standard protocol and with a Vivid E9 
Dimension system (Vingmed, General Electric, Milwaukee, WI, USA); all recordings were stored 
digitally for offline analysis. Images were recorded prospectively and analyzed at the core echo 
laboratory in a blinded fashion. LV volumes and LVEF were calculated via the Simpson’s biplane 
method in apical four- and two-chamber views.   
 
Two-dimensional speckle-tracking echocardiography (2D-STE) 
2D-STE longitudinal strain analyses were performed with high-frame-rate (60-90 frames/s), gray-scale 
images in the conventional apical 4-, 3-, and 2-chamber views (10). The endocardial border was 
manually traced at end-systole, and the software automatically traced the region of interest within the 
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myocardium. The integrity of speckle tracking was detected automatically and visually evaluated; if 
the tracking was poor, the tracing for the region of interest was manually adjusted. Segments with 
persistently inadequate tracking and studies with two or more segments inadequately tracked were 
excluded from analysis. Longitudinal strain was calculated as the change in length divided by the 
original length of the speckle pattern over the cardiac cycle and expressed as a percentage; myocardial 
longitudinal lengthening was represented as positive strain and myocardial longitudinal shortening 
was represented as negative strain (10). Peak systolic longitudinal strain was automatically displayed 
as a 17-segment polar map, which included the strain values for each segment and a mean global 
longitudinal strain (GLS) value for the entire LV. Overall, segmental analyses were performed by 
matching NOGA, SPECT, and echo images with the bull-eye technique and then correlating the 
segments to define the injected and non-injected segments. 
 
Statistical analysis 
Data are presented as mean±standard error of the mean for quantitative variables and as percentages 
for categorical variables. Data collected for the same patient at different time points were evaluated as 
repeated measures data, and the trend of the response over time was fit via linear mixed effects 
models. Random intercept and random slope models were used to accommodate heterogeneity in the 
intercepts and slopes for each individual patient’s regression line. Mixed models were adjusted for 
age, sex, and cardiology departments. When the results of the mixed model test were significant, the 
Wilcoxon signed-rank test was used for post-hoc pairwise analysis, and false discovery rate control 
was used to correct for multiple comparisons. Testing was two-tailed, and the level of significance was 
set at p≤0.05. Statistical analyses were performed using SAS statistical software, release 9.4 (SAS 
Institute Inc, Cary, North Carolina, U.S.A.).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 11 
RESULTS 
 
The patient follow-up period began at the time of cell administration. Safety and clinical outcomes 
were evaluated from data collected over a 2-year follow-up period, while cardiac function and quality 
of life were evaluated from data collected during the first year of follow-up. 
 
Patient demographics and distribution 
A total of 10 patients from the University Hospitals of Toulouse and Nantes were enrolled in the 
MESAMI 1 study from December 2009 to January 2012. All patients had persistent myocardial 
ischemia in 2 or more of 17 LV segments (assessed via Thallium-201 SPECT imaging) and a medical 
history with at least one myocardial infarction. Mean duration of CAD was 9.5±2.4 years, and nine 
patients had more than one affected vessel. Seven patients had undergone either PCI or CABG. All 
patients participated in each of the 4 stages of the study (eligibility assessments, bone marrow 
aspiration and MSC isolation/expansion, MSC injection, and follow-up). None of the patients 
withdrew consent and all completed the full two-year follow-up period. 
 
Characterization of the cell therapy product 
After expansion, cell viability measurements approached 95% in each preparation; CD73, CD90, and 
CD13 were each expressed by more than 98% of cells, and less than 1% of cells expressed CD45 or 
CD14 (Table 2). The results from karyotype analyses were normal, and there were no reports of cell 
contamination or other safety concerns. 
 
Primary endpoint analysis: feasibility and safety one month after cell injection 
Both primary endpoints, feasibility (i.e., successful completion of the bone marrow aspiration, cell 
culture, and percutaneous intramyocardial injection procedures) and safety (i.e., absence of SAEs) at 
the one-month time point, were met in all patients (n=10). Bone marrow aspirates (16.8±0.6 mL) were 
obtained from each patient without complications and with no need for post-operative analgesia. 
MSCs were successfully isolated from all bone-marrow samples and expanded, and each patient was 
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successfully administered a total of 40×10
6
 to 100×10
6
 (mean: 61.5±7.0×10
6
) MSCs via 
intramyocardial injections at 10 to 16 locations (mean: 13.7±0.5). The injections were performed 
without complications and were well tolerated with no allergic or local inflammatory reactions, no 
injection-related toxicities or subsequent toxicities that were attributable to the MSC injection, no 
incidents of infection or pericardial effusion, and no sign of tumor development. No SAEs were 
reported: there were no incidents of re-hospitalization, stroke, bleeding, or MACEs, and no deaths. 
Two patients each had one adverse event during the injection procedure: one patient experienced a 
vasovagal reaction caused by arterial puncture, and one patient experienced non-sustained ventricular 
tachycardia that resolved spontaneously and was not attributable to the cell therapy product. The 
tachycardia was caused by mobilization of the catheter into the LV and occurred in a patient whose 
medical history included ventricular arrhythmia.   
 
Two-year safety assessment 
Eleven SAEs were reported during the full two-year follow-up period (Table 3), none of which were 
related to the study intervention or the cell therapy product (as determined via Data Safety Monitoring 
Board review). Only one SAE occurred during the first year of follow-up, and it was attributable to the 
development of a new condition that required nasal surgery. Of the ten SAEs that occurred during the 
second year of follow-up, six (four of which occurred in the same patient) were attributable to 
progression of the pre-existing ischemic heart failure, and the other four were attributable to the 
progression of another pre-existing condition (diabetes, renal failure, anaemia, or peripheral arterial 
disease). 
 
Secondary endpoints (efficacy)  
Echocardiographic assessments of LV function 
Mean LVEF was significantly higher at the 3-month follow-up time point (35.9±2.1%) than during 
baseline assessments performed before cell administration (29.4±2.0%; p<0.01, n=10), and the 
improvement was maintained at the 1-year follow-up time point (35.7±2.5%; p<0.01 versus baseline, 
n=10) (Figure 2A). Mean LVESV also improved from baseline (167.8±18.8 mL) to Month 3 
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(151.9±17.7 mL), and the improvement achieved significance by Month 12 (156.1±28.6 mL; p=0.04 
versus baseline) (Figure 2B). Mean LVEDV was similar at all three time points (baseline: 232.2±19.8 
mL, Month 3: 235.3±20.6 mL, Month 12: 232.3±29.3; p=0.31). 
 
2D-STE assessments of segmental contraction  
Assessments of the wall motion score index (WMSI) for the entire LV (p=0.917), the global 
longitudinal strain (GLS) (p=0.09), and the mean longitudinal strain scores (i.e., the extent of 
contraction in the longitudinal direction, expressed as a percentage) (Figures 2C-D) for control 
segments of the LV that were not injected with MSCs (-5.5±6.9 at M0 to -7.2±9.5 at M3 and -7.8±6.9 
at M12; p=0.157) did not change significantly over time; however, the extent of contraction increased 
significantly from baseline (-2.1±6.3%) to Month 3 (-7.3±5.8%; p<0.05) in segments that received cell 
injections, and this significant improvement was maintained at Month 12 (-5.5±5.4%; p<0.05 versus 
baseline). 
 
SPECT assessments of myocardial ischemia and viability  
Summed stress scores were significantly lower (signaling a decline in myocardial ischemia) at Month 
3 (25.3±3.9) than at baseline (34.1±0.6; p=0.031) (Figure 3A); SSS was also lower at Month 12 than at 
baseline, but not significantly (p=0.05), and neither SDS or SRS changed significantly from baseline 
to Month 3 or from baseline to Month 12 (Figure 3B and 3C). Qualitative analyses of the number of 
non-ischemic myocardial segments (p=0.07), the number of segments with reversible ischemia 
(p=0.44), and the number of segments with non-reversible ischemia (p=0.09) were also unchanged 
throughout the 12-month follow-up period. Myocardial viability assessments and the number of viable 
segments did not change significantly (p=0.234) from baseline (14.6±3) to Month 3 (13.8±3) or Month 
12 (12.7±3).  
 
Functional status and quality of life  
Mean NYHA patient class improved significantly from baseline (2.6±0.2) to Month 12 (2.1±0.2; 
p<0.05); the proportion of patients in Class I increased from 0% at baseline to 10% (n=1) at Month 3 
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and to 20% (n=2) at Month 12, while the proportion in Class III declined by half, from 60% (n=6) at 
baseline to 30% (n=3) at Month 12 (Figure 4). Quality of life scores (MLHFQ) improved significantly 
from baseline to Month 3 (p<0.05), but not from baseline to Month 12, while measurements of 
exercise peak oxygen consumption tended to improve over time (VO2 [mL/min per kg], baseline: 
12.6±1.3, Month 3: 13.2±1.8, Month 12: 14.1±1.7, p=0.62), and the trend for the 6-minute walk test 
was significant (baseline: 354.6±25.5 m, Month 3: 360.2 ± 32.4 m, Month 12: 376.1±26.7 m; p=0.05). 
Changes to the patients’ drug treatment regimens were minor and not significant (Table 4); beta-
blocker use increased in 2 patients (carvedilol: from 18.75 mg to 37.5 mg; bisoprolol from 7.5 mg to 
10 mg), the dose of angiotensin-converting enzyme (ACE) inhibitors increased in 1 patient (ramipril: 
from 5 mg to 7.5 mg), and loop-diuretic use declined in 1 patient (furosemide: from 200 mg to 12 mg). 
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DISCUSSION 
 
The results from our MESAMI 1 trial suggest that autologous MSCs can be safely and feasibly 
harvested, expanded, and transendocardially injected (via a NOGA-guided catheter) into the hearts of 
patients with severe, chronic, reversible myocardial ischemia and impaired cardiac function, and that 
this treatment approach may be associated with improvements in myocardial performance and patient 
functional status. All four stages of the protocol were successfully completed for each of the 10 
enrolled patients: MSC harvest was accomplished without complications and with no need for post-
operative analgesia, the expansion protocol yielded 85.3±11.3×10
6
 cells per patient (~95% of which 
were viable), and the injection procedure was well tolerated with no allergic or local inflammatory 
reactions, no injection-related toxicities, and no SAEs. Eleven SAEs were reported during the two-
year follow-up period, but none of them were related to the study intervention, and significant 
improvements in echocardiographic assessments of LVEF and/or LVESV were observed at Month 3 
(LVEF) and/or Month 12 (LVEF and LVESV) after cell administration. Patients’ NYHA functional 
class and 6-minute walk test also improved significantly during the 12-month follow-up period, while 
clinical assessments of patient function (VO2) and quality of life (MLHFQ) tended to improve over 
time, but not significantly.   
The safety of MSC injection in patients with chronic ischemic cardiomyopathy is also supported by 
results from the TAC-HFT trial (5), a randomized, controlled study that included 19 patients who were 
treated with injected MSCs and 10 who received injections of placebo. However, the inclusion criteria 
for our MESAMI 1 study (e.g., LVEF <35% and reversible ischemia in two or more of the 17 AHA-
defined LV segments) selected for patients in whom the extent of cardiac dysfunction was 
considerably more severe. For example, 60% of patients in our study were NYHA Class III, compared 
to 10.5% of patients who were administered MSCs in the TAC-HFT trial, and mean LVEF at baseline 
also differed substantially (MESAMI 1: 29.4±2.0%, TAC-HFT: 35.7±9%). MESAMI 1-trial 
participants were also more severely compromised than patients in either of two randomized, 
controlled studies that investigated the use of injected bone marrow mononuclear cells for the 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 16 
treatment of myocardial disease: the FOCUS-CCTRN trial (11), which was open to patients with 
chronic CAD whose LVEF was as high as 45%, and a study reported by van Ramshorst et al. (12), 
which included patients with refractory angina pectoris whose mean baseline LVEF was 56±12% in 
the cell-treatment group. Thus, the results reported here suggest that autologous MSC injection may be 
safe, even for patients whose myocardial disease is particularly advanced.  
 
The improvements in LVEF reported here were not associated with MSC injection in the TAC-HFT 
trial (5). This apparent discrepancy may have evolved from our use of the NOGA catheter, which 
(unlike the system used in the TAC-HFT trial) enabled us to evaluate the viability and extent of 
myocardial dysfunction for each injection site electromechanically at the time of cell administration.  
Scar size was significantly improved in MSC-treated patients from the TAC-HFT study but could not 
be evaluated here, because the study participants had an ICD, as recommended by the 2010 ESC 
guidelines for patients whose LVEF is ≤35% (13). Whether the observed improvement in scar size 
reported in the TAC-HFT trial evolved from a decline in fibrosis, rather than an increase in the 
thickness of the myocardium, has yet to be determined. Furthermore, the 6.5% improvement in LVEF 
observed in our MESAMI 1 patients is very similar to the 6.2% increase reported for the MSC therapy 
group in the recently published MSC-HF trial (6.2%) (14), and although bone marrow mononuclear 
cells (rather than MSCs) were associated with significant improvements in LVEF after administration 
to patients in the FOCUS-CCTRN trial, changes in LVESV, maximum oxygen consumption, and the 
occurrence of MACE were not significant (11). MSCs also display trophic properties and secrete 
paracrine factors associated with improvements in apoptosis, inflammation, angiogenesis, and fibrosis 
(15), which suggests that they may be more effective than BMCs for the treatment of myocardial 
disease, particularly in patients with heart failure. 
 
The improvements in LVEF observed in patients from the MESAMI 1 trial were matched by 
significant increases in longitudinal strain measurements and accompanied by significant declines in 
SSS at Month 3. This observation is encouraging, because SSS is an independent predictor of adverse 
cardiac events in patients with a history of previous myocardial infarction (16); however, significant 
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declines were not maintained in SSS measurements at Month 12, which suggests that the progression 
of ischemic myocardial disease may not be halted by a single treatment with MSC therapy. Thus, 
patients may require a series of treatments administered over an extended period to obtain maximal 
benefit, but the studies required to develop such an approach have yet to be initiated.  
 
The layers of muscle fibers in the heart are aligned in multiple orientations (17) and produce a pattern 
of structural changes (i.e., the deformation profile) as the LV contracts that includes twists, rotations, 
and shortening of the myocardial wall (18). Thus, movements within the myocardial wall are difficult 
to monitor via Tissue Doppler Imaging, because the technique requires sufficient alignment between 
the ultrasound beam and the direction of motion. 2D-STE assessments are free of these alignment 
issues, because they track the movement of minute regions of the myocardium, each of which can be 
identified by a unique and relatively stable pattern of “speckles,” and the value of this technique for 
characterizing myocardial contractile activity has been demonstrated in a number of studies. 
Longitudinal myocardial deformation analyses can provide strong prognostic information in patients 
with heart failure (23), and specific characteristics associated with the deformation profile can be used 
to detect the presence of clinical conditions that cannot be identified via conventional kinetic analyses, 
such as WMSI (19-22). Peak systolic longitudinal strain measurements also correlate well with infarct 
mass over a wide range of infarct sizes and locations, and segmental analyses are capable of 
identifying the relationship between the severity of contractile dysfunction and the amount of scar 
tissue in each segment (24). Roes, et al. (25) found that in a population of 90 patients with chronic 
ischemic LV dysfunction, mean strain was –10.4±5.2% in segments without scar tissue versus 
0.6±4.9% in segments with transmural scars, and that a strain of –4.5% differentiated between viable 
and scarred segments with 81.2% sensitivity and 81.6% specificity. Thus, although measurements of 
WMSI and global longitudinal strain were unchanged in our MESAMI 1 trial, the significant 
improvements observed in cell-treated segments (from –2.1±6.3% at M0 to –7.3%±5.8 at M3 and –
5.5±5.4% and M12; p=0.0005), but not in untreated segments, strongly suggests that the injected cells 
improved myocardial viability. These results emphasize the importance of identifying and targeting 
specific regions of the myocardium for cell delivery (e.g., by using the 3D-NOGA system) and may be 
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particularly informative, because comparisons between individual segments are unlikely to be 
confounded by changes in the patient’s drug regimen or medical care. 
 
Study limitations 
We acknowledge that our MESAMI 1 trial was conducted with a very small number of patients (n=10) 
and did not include a placebo group. Although the outcome appears to be positive, it is difficult to 
reach meaningful conclusions. Thus, our results must be interpreted with appropriate caution and used 
primarily for the development of new hypotheses that can be evaluated in subsequent trials. 
 
Perspectives  
The MESAMI 1 trial is part of the feasibility and safety phase of the ongoing MESAMI program, 
which is dedicated to establishing the use of MSCs as an advanced-therapy medicinal product 
(ATMP), and to obtaining Marketing Authorization for MSCs in the European Union through the 1
st
 
Cell Therapy European Platform (Cell For Cure, Les Ullis, France). According to European 
regulations, the designation of MSCs as an ATMP requires the use of production processes that meet 
the guidelines of Good Manufacturing Practices (GMP). Meeting the GMP standard is a worldwide 
industrial challenge for the production of any cell-therapy product, including MSCs, which are among 
the most promising tools for cell-based regenerative medicine. The success of the MESAMI program 
will lead to the development of a mastered production process with relevant and reproducible controls 
that will ensure the efficient production of a well-defined, safe, high-quality, and effective MSC 
product. Production of mesenchymal stromal cells according to good manufacturing practices has been 
previously and extremely detailed by our group (7). The efficiency of our current production process is 
now being tested in a larger patient population via a randomized, double-blind, multicenter, placebo-
controlled clinical study (the MESAMI 2 trial Clinical Trial Registration: Unique identifier: 
NCT02462330). 
 
CONCLUSION 
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Our results suggest that autologous MSCs can be safely administered to the hearts of patients with 
severe, chronic, reversible myocardial ischemia and impaired cardiac function and may be associated 
with improvements in cardiac performance, LV remodeling, and patient functional status.  
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FIGURE LEGENDS 
 
Figure 1. MESAMI 1 Trial Flow Diagram (n=10). 
 
Figure 2. Assessments of myocardial function and remodeling. 
(A) Echocardiographic assessments of left-ventricular (LV) ejection fractions and (B) LV end-systolic 
and end-diastolic volumes (LVESV and LVEDV, respectively) were performed before cell 
administration (M0) and 3 months (M3) and 12 months (M12) afterward (N=10). (C-D) Two-
dimensional speckle-tracking echocardiography was performed at M0, M3, and M12 to evaluate the 
longitudinal strain (i.e., the extent of contraction in the longitudinal direction) in (C) sections from the 
ischemic region of the LV that had been treated with injected MSCs and in (D) untreated regions of 
the LV (N=4). Strain was calculated as (length after contraction – length before contraction)/(length 
before contraction) and expressed as a percentage. **p≤0.01, *p≤0.05, ns: not significant.  
 
Figure  3. Assessments of myocardial perfusion. 
Single-photon emission computed tomography assessments of (A) the summed stress score (SSS), (B) 
the summed rest score (SRS), and (C) the summed difference score (SDS) were performed before cell 
administration (M0, n=10) and 3 months (M3, n=10) and 12 months (M12, n=10) afterward. Data for 
each individual patient are traced with a thin black line and represent the mean of the values obtained 
for each of the 17 AHA-defined segments of the left ventricle (SEMs have been omitted for visual 
clarity). Data for the means±SEMs for all available patients at each time point are traced with a heavy 
black line. *p≤0.05, ns: not significant. 
 
Figure  4. Assessment of New York Heart Association functional class. 
Evaluations were performed before cell administration (M0) and 3 months (M3) and 12 months (M12) 
afterward. Data are presented as the percentage of patients in each functional category. *p<0.05, ns: 
not significant (N=10).  
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Table 1. Baseline Characteristics  
Sex, number of men (%)  9 (90)  
Age, years, mean ± SEM 57.2 ± 1.8  
BMI, kg/m
2
, mean ± SEM 29.5 ± 1.5  
Systolic blood pressure, mmHg, mean ± SEM  121 ± 4  
Diastolic blood pressure, mmHg, mean ± SEM  72 ± 2  
Resting heart rate, bpm, mean ± SEM 70 ± 4  
Duration of disease, years, mean ± SEM 9.5 ± 2.4  
CCS functional class, mean ± SEM 1.8 ± 0.5  
NYHA functional class, mean ± SEM 2.6 ± 0.2  
  
Risk factors  n (%) 
Smoking  9 (90)  
Hypertension  4 (40)  
Dyslipidemia  7 (70)  
Diabetes  5 (50)  
Family history  2 (20)  
Obesity  5 (50)  
  
Past medical history  n (%) 
Peripheral arterial disease  4 (40)  
Ventricular arrhythmia  3 (30)  
Myocardial infarction  10 (100)  
Pectoris angina  7(70)  
Multivessel disease 10 (100) 
   3-vessels  6 (60) 
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   2-vessels  3 (30) 
   1-vessel  1 (10) 
PCI  6 (60)  
CABG  1 (10)  
  
Medications at time of randomization n (%) 
   ACE or ARB  10 (100)  
   Beta-blockers  10 (100)  
   Diuretics (furosemide, mineralo-corticoide)  10 (100)  
   Statins  10 (100)  
   Nitrates 5 (50)  
BMI: body mass index, CCS: Canadian Cardiovascular Society, NYHA: New York Heart Association, 
PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft, ACE: angiotensin 
converting enzyme, ARB: angiotensin II receptor blocker.  
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Table 2. Characteristics of the cell therapy product  
Characteristic Mean ± SEM 
Total number of 
mesenchymal stromal cells  (×10
6
)  
85.3 ± 11.3  
Viability of cells (%)  94.9 ± 1.2  
Surface Markers Mean ± SEM 
CD45 (%)  0.3 ± 0.1  
CD14 (%)  0.5 ± 0.2  
CD73 (%)  98.4 ± 1.0  
CD90 (%)  99.3 ± 0.2  
CD13 (%)  99.5 ± 0.1  
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Table 3. Serious Adverse Events (SAEs) 
SAE 
Number* 
Time of 
SAE Description of SAE  
Defining 
Criteria 
Relationship 
to Procedure  
Imputability  
1 M9 Nasal surgery assessment  
Required 
in-patient 
hospitalization  
Not related  Other  
2 M13 
Hospitalization for planned 
coronary angiogram  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
3 M17 
Scheduled hospitalization for 
assessment of operability for a 
possible mechanical 
circulatory support and pre-
transplant assessment  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
4 M17 
Global cardiac 
decompensation with 
lipothymia and atrial 
fibrillation  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
5 M18 
Renal failure, anaemia, and 
slight cardiac overload after 
rehydration and decrease of 
diuretic doses  
Required 
in-patient 
hospitalization  
Not related  
Evolution of other 
pre-existing disease  
6 M20 
Scheduled hospitalization for 
right catheterization and 
inscription on transplant 
waiting list  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
7 M20 
Acute pulmonary edema on 
severe ischemic 
cardiomyopathy  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
8 M21 
Scheduled hospitalization for 
reassessment of PAD, 
revascularization of superficial 
femoral and tibial right arteries 
with correct result  
Required 
in-patient 
hospitalization  
Not related  
Evolution of other 
pre-existing disease  
9 M22 
Congestive heart failure: 
increased dyspnoea  
Required 
in-patient 
hospitalization  
Not related  
Disease 
progression 
10 M22 
Scheduled hospitalization for 
femoral artery stenting in 
patient with symptomatic PAD 
Required 
in-patient 
hospitalization  
Not related  
Evolution of other 
pre-existing disease  
11 M24 
Adaptation of diabetic 
treatment  
Required 
in-patient 
hospitalization  
Not related  
Evolution of other 
pre-existing disease  
 
*SAE number 2, 3, 7, and 9 occurred in the same patient; SAE number 5 and 8 occurred in the same 
patient; SAE number 4 and 11 occurred in the same patient.     
M: month, CAD: coronary artery disease, PAD: peripheral artery disease.  
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Table 4. Medical Treatment. 
 Baseline M12 P-value 
ACE or ARB (% maximal dose*) 85% 87.5% >0.9 
Beta-blockers (% maximal dose*) 60.6% 65% 0.5 
Loop diuretics (furosemide), mean (SEM), mg 68±16.5 62±10.1 >0.9 
Mineralocorticoid receptor antagonists, mean 
(SEM), mg 
26.3±4.7 22.5±5.8 0.5 
ACE: angiotensin converting enzyme inhibitors, ARB: angiotensin 2 receptor blockers.  
*Expressed as the percentage of maximum expected dose for the specific drug administered (ACE: 
enalapril, perindopril, or ramipril; ARB: candesartan; beta-blockers: carvedilol and bisoprolol). 
